Neurizon Therapeutics Limited has released a press release.
Appendix 4E and 2026 Annual Report
Earlier from Neurizon Therapeutics
- Neurizon Enters Strategic R&D Financing Facility
- HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
- Neurizon executes long-term supply agreement with Elanco
- HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule